Legislative and regulatory issues affecting SMID rare disease biotech companies. FDA approvals of rare diseases.
2026 · 2nd Quarter (Apr 1 - June 30)
AMICUS THERAPEUTICS, INC.
Filed by CAPITOL COUNSEL LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Termination
- Posted
- Jul 16, 2026
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- CAPITOL COUNSEL LLC
- Filing UUID
- 81d5fadb-ecfb-4ef5-955e-130f160ced60
- Termination date
- Apr 15, 2026
Literal source text
Lobbying issues and bill citations
Legislative and regulatory issues affecting SMID rare disease biotech companies.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.